Using a standardized treatment system for acute ischemic stroke in Xi'an

Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an

This study looks at how a quick treatment system for acute ischemic stroke helps patients in Xi'an recover and what happens to them in the following months.

Quick facts

• Study type: Observational
• Enrollment: 3600 (estimated)
• Ages: 18 Years to 100 Years
• Sex: All
• Sponsor: Xi'an No.3 Hospital (other gov)
• Locations: 1 site (Xi'an, Shaanxi)
• Trial ID: NCT05424978 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the real-world application of a standardized green channel treatment system for patients with acute ischemic stroke in Xi'an. It involves collecting clinical data from patients who received this treatment within 24 hours of stroke onset. The study will assess various outcomes, including prognosis, mortality rates, incidence of cerebral hemorrhage, pneumonia, and stroke recurrence after 90 days. The approach emphasizes rapid assessment and intervention to improve patient outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with acute ischemic stroke within 24 hours of onset.

Not a fit: Patients with strokes caused by brain tumors, trauma, or blood diseases, as well as those with severe hepatic or renal insufficiency, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the treatment protocols for acute ischemic stroke, potentially improving recovery rates and reducing complications.

How similar studies have performed: While this approach is based on established treatment protocols, the specific application of a standardized green channel system in this context may provide novel insights into its effectiveness.

Eligibility criteria

Inclusion Criteria:

* 18 years old;
* Consistent with the diagnosis of acute ischemic stroke;
* 24 hours from onset to enrollment;
* Informed consent

Exclusion Criteria:

* Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);
* Stroke patients caused by brain tumor, brain trauma and blood diseases;
* Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;
* Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;
* Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);
* Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;
* Other diseases that limit neurological function evaluation or affect patient follow-up;
* A woman planning to be pregnant or breastfeeding;
* Currently participating in other clinical trials;
* Refuse to participate in the registration of investigators

Where this trial is running

Xi'an, Shaanxi

• Xi 'an No.3 Hospital — Xi'an, Shaanxi, China (RECRUITING)

Study contacts

• Study coordinator: Mingze Chang, Doctor

Conditions: Acute Ischemic Stroke, Thrombolysis, Endovascular Treatment